I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 54% ± 21% | |
| microglial cell | 3 studies | 22% ± 6% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 54% ± 21% | |
| microglial cell | 3 studies | 22% ± 6% |
Insufficient scRNA-seq data for expression of LIPC at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 4631.24 | 226 / 226 | 99% | 57.13 | 401 / 406 |
| kidney | 100% | 474.40 | 89 / 89 | 93% | 33.10 | 835 / 901 |
| pancreas | 96% | 52.93 | 315 / 328 | 63% | 2.53 | 112 / 178 |
| bladder | 81% | 29.24 | 17 / 21 | 38% | 2.87 | 191 / 504 |
| thymus | 94% | 64.39 | 613 / 653 | 24% | 0.75 | 147 / 605 |
| ovary | 82% | 33.22 | 148 / 180 | 20% | 0.44 | 86 / 430 |
| ureter | 0% | 0 | 0 / 0 | 100% | 1.90 | 1 / 1 |
| spleen | 98% | 67.24 | 237 / 241 | 0% | 0 | 0 / 0 |
| skin | 86% | 70.81 | 1547 / 1809 | 7% | 0.16 | 33 / 472 |
| lung | 79% | 29.76 | 455 / 578 | 14% | 0.62 | 159 / 1155 |
| stomach | 73% | 25.25 | 262 / 359 | 19% | 1.12 | 54 / 286 |
| intestine | 77% | 43.53 | 742 / 966 | 12% | 0.81 | 64 / 527 |
| esophagus | 67% | 24.74 | 961 / 1445 | 20% | 1.02 | 37 / 183 |
| brain | 64% | 37.66 | 1696 / 2642 | 22% | 0.39 | 153 / 705 |
| heart | 77% | 35.38 | 664 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 72% | 37.77 | 670 / 929 | 0% | 0 | 0 / 0 |
| breast | 64% | 26.53 | 295 / 459 | 4% | 0.10 | 47 / 1118 |
| adipose | 67% | 35.68 | 812 / 1204 | 0% | 0 | 0 / 0 |
| prostate | 66% | 22.35 | 162 / 245 | 1% | 0.15 | 4 / 502 |
| uterus | 44% | 13.76 | 74 / 170 | 13% | 0.59 | 58 / 459 |
| blood vessel | 47% | 15.56 | 631 / 1335 | 0% | 0 | 0 / 0 |
| adrenal gland | 11% | 2.05 | 28 / 258 | 2% | 0.31 | 5 / 230 |
| lymph node | 0% | 0 | 0 / 0 | 10% | 0.13 | 3 / 29 |
| muscle | 6% | 1.18 | 47 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 2% | 0.10 | 1 / 45 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0070328 | Biological process | triglyceride homeostasis |
| GO_0034382 | Biological process | chylomicron remnant clearance |
| GO_0034372 | Biological process | very-low-density lipoprotein particle remodeling |
| GO_0034373 | Biological process | intermediate-density lipoprotein particle remodeling |
| GO_0008203 | Biological process | cholesterol metabolic process |
| GO_0043691 | Biological process | reverse cholesterol transport |
| GO_0034375 | Biological process | high-density lipoprotein particle remodeling |
| GO_0019433 | Biological process | triglyceride catabolic process |
| GO_0006633 | Biological process | fatty acid biosynthetic process |
| GO_0034638 | Biological process | phosphatidylcholine catabolic process |
| GO_0034374 | Biological process | low-density lipoprotein particle remodeling |
| GO_0042632 | Biological process | cholesterol homeostasis |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0034364 | Cellular component | high-density lipoprotein particle |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0008201 | Molecular function | heparin binding |
| GO_0004620 | Molecular function | phospholipase activity |
| GO_0008970 | Molecular function | phospholipase A1 activity |
| GO_0004465 | Molecular function | lipoprotein lipase activity |
| GO_0052739 | Molecular function | phosphatidylserine 1-acylhydrolase activity |
| GO_0052740 | Molecular function | 1-acyl-2-lysophosphatidylserine acylhydrolase activity |
| GO_0004806 | Molecular function | triglyceride lipase activity |
| GO_0034185 | Molecular function | apolipoprotein binding |
| GO_0004622 | Molecular function | lysophospholipase activity |
| GO_0102545 | Molecular function | phosphatidyl phospholipase B activity |
| GO_0030169 | Molecular function | low-density lipoprotein particle binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | LIPC |
| Protein name | Hepatic lipase Hepatic triacylglycerol lipase (EC 3.1.1.32) (EC 3.1.1.5) (Lipase member C) (Lysophospholipase) (Phospholipase A1) Hepatic triacylglycerol lipase (HL) (Hepatic lipase) (EC 3.1.1.3) (Lipase member C) (Lysophospholipase) (EC 3.1.1.5) (Phospholipase A1) (EC 3.1.1.32) Hepatic triacylglycerol lipase (EC 3.1.1.3) (EC 3.1.1.32) (EC 3.1.1.5) (Lipase member C) (Lysophospholipase) (Phospholipase A1) |
| Synonyms | HTGL |
| Description | FUNCTION: Catalyzes the hydrolysis of triglycerides and phospholipids present in circulating plasma lipoproteins, including chylomicrons, intermediate density lipoproteins (IDL), low density lipoproteins (LDL) of large size and high density lipoproteins (HDL), releasing free fatty acids (FFA) and smaller lipoprotein particles . Also exhibits lysophospholipase activity (By similarity). Can hydrolyze both neutral lipid and phospholipid substrates but shows a greater binding affinity for neutral lipid substrates than phospholipid substrates (By similarity). In native LDL, preferentially hydrolyzes the phosphatidylcholine species containing polyunsaturated fatty acids at sn-2 position . . |
| Accessions | ENST00000433326.2 ENST00000414170.7 B9TXP1 ENST00000299022.10 P11150 ENST00000356113.10 A6H8L5 E7EUJ1 E7EUK6 |
